
    
      The study will consist of 4 visits: an enrollment/screening visit, a control visit with pump
      suspension prior to treatment with canagliflozin, a visit with pump suspension while on
      canagliflozin and an end of study visit. Each of the pump suspension visits will be
      approximately 20-hour overnight admissions to the Hospital Research Unit (HRU).
    
  